Alder BioPharmaceuticals, Inc. (ALDR) Shares Sold by Fiera Capital Corp

Fiera Capital Corp lowered its stake in shares of Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) by 10.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 145,658 shares of the biopharmaceutical company’s stock after selling 16,418 shares during the quarter. Fiera Capital Corp owned about 0.29% of Alder BioPharmaceuticals worth $1,667,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Janus Capital Management LLC increased its position in shares of Alder BioPharmaceuticals by 4.7% during the first quarter. Janus Capital Management LLC now owns 5,167,085 shares of the biopharmaceutical company’s stock valued at $107,473,000 after buying an additional 230,044 shares during the period. Wellington Management Group LLP increased its position in shares of Alder BioPharmaceuticals by 0.7% during the first quarter. Wellington Management Group LLP now owns 3,640,788 shares of the biopharmaceutical company’s stock valued at $75,728,000 after buying an additional 26,791 shares during the period. Vanguard Group Inc. increased its position in shares of Alder BioPharmaceuticals by 6.0% during the first quarter. Vanguard Group Inc. now owns 3,438,702 shares of the biopharmaceutical company’s stock valued at $71,524,000 after buying an additional 194,185 shares during the period. Redmile Group LLC increased its position in shares of Alder BioPharmaceuticals by 107.5% during the first quarter. Redmile Group LLC now owns 1,909,886 shares of the biopharmaceutical company’s stock valued at $39,726,000 after buying an additional 989,336 shares during the period. Finally, State Street Corp increased its position in shares of Alder BioPharmaceuticals by 1.0% during the first quarter. State Street Corp now owns 1,777,113 shares of the biopharmaceutical company’s stock valued at $36,966,000 after buying an additional 18,426 shares during the period. Institutional investors own 76.16% of the company’s stock.

Shares of Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) opened at 10.50 on Tuesday. Alder BioPharmaceuticals, Inc. has a one year low of $8.60 and a one year high of $35.62. The stock’s market cap is $710.99 million. The firm has a 50-day moving average of $9.65 and a 200-day moving average of $15.85.

Alder BioPharmaceuticals (NASDAQ:ALDR) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.48) EPS for the quarter, beating the consensus estimate of ($1.67) by $0.19. The business had revenue of $0.68 million during the quarter. During the same period in the prior year, the company posted ($0.79) EPS. The business’s quarterly revenue was up 518.2% on a year-over-year basis. On average, equities research analysts expect that Alder BioPharmaceuticals, Inc. will post ($5.71) earnings per share for the current fiscal year.

In other Alder BioPharmaceuticals news, Director Stephen M. Dow purchased 25,000 shares of Alder BioPharmaceuticals stock in a transaction dated Tuesday, July 18th. The stock was acquired at an average price of $10.00 per share, for a total transaction of $250,000.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 10.60% of the company’s stock.

ALDR has been the topic of several research analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $36.00 price target on shares of Alder BioPharmaceuticals in a research report on Friday, June 9th. Leerink Swann reiterated an “outperform” rating and set a $32.00 price target on shares of Alder BioPharmaceuticals in a research report on Monday, June 12th. ValuEngine upgraded shares of Alder BioPharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, June 20th. Credit Suisse Group cut shares of Alder BioPharmaceuticals from an “outperform” rating to a “neutral” rating and reduced their price target for the company from $30.00 to $17.00 in a research report on Wednesday, June 28th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and set a $47.00 price target on shares of Alder BioPharmaceuticals in a research report on Wednesday, June 28th. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $30.62.

COPYRIGHT VIOLATION NOTICE: “Alder BioPharmaceuticals, Inc. (ALDR) Shares Sold by Fiera Capital Corp” was originally posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/09/19/alder-biopharmaceuticals-inc-aldr-shares-sold-by-fiera-capital-corp.html.

About Alder BioPharmaceuticals

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Want to see what other hedge funds are holding ALDR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR).

Institutional Ownership by Quarter for Alder BioPharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply